Showing results (111-120 of 125) with videos related to

Sort By:
Pageof 13
International Journal of Clinical Oncology|June 4, 2024
Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA studyKenji Tanabe, Shuichiro Kobayashi, Yuya Maezawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 4, 2025
Real-World Outcomes of First-Line Systematic Treatment in Locally Advanced or Metastatic Upper Urinary Tract Urothelial Carcinoma With Renal Impairment (YUSHIMA Study)Tomoki Kimura, Motohiro Fujiwara, Yuya Maezawa, et al.
Cancer Medicine|September 5, 2020
Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary studyHiroshi Fukushima, Toshiki Kijima, Shohei Fukuda, et al.
Japanese Journal of Clinical Oncology|March 16, 2026
Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04)Ichiro Yonese, Fumitaka Koga, Masahiro Toide, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|June 8, 2026
Prognostic Value of Inflammatory Biomarkers as Continuous Variables in Metastatic Renal Cell Carcinoma: Linearity Assessment, Proportional Hazards Assumption Testing, and Time-Varying EffectsShugo Yajima, Soichiro Yoshida, Shohei Fukuda, et al.
International Urology and Nephrology|April 21, 2026
External validation of the Meet-URO score in Japanese metastatic renal cell carcinoma patients receiving first-line immune-combinationsShugo Yajima, Soichiro Yoshida, Shohei Fukuda, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 22, 2025
Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study)Takahiko Soma, Hajime Tanaka, Yuki Nakamura, et al.
European Urology Focus|July 21, 2017
Ureteral Involvement Is Associated with Poor Prognosis in Upper Urinary Tract Urothelial Carcinoma Patients Treated by Nephroureterectomy: A Multicenter Database StudyYuma Waseda, Kazutaka Saito, Junichiro Ishioka, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|July 22, 2014
Equivalent survival and improved preservation of renal function after distal ureterectomy compared with nephroureterectomy in patients with urothelial carcinoma of the distal ureter: a propensity score-matched multicenter studyHiroshi Fukushima, Kazutaka Saito, Junichiro Ishioka, et al.
International Urology and Nephrology|August 7, 2026
C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study)Shugo Yajima, Soichiro Yoshida, Hiroyuki Sato, et al.
Pageof 13